linjc16/ctgov huggingface dataset:
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular

Study Overview
=================
Brief Summary
-----------------
Develop a new scoring system for HCC patients with tumor rupture.

Detailed Description
-----------------
There has been no special prognostic scoring system for HCC patients with tumor rupture in the literature. In this work, we obtained all survival risk factors of ruptured HCC patients who underwent partial hepatectomy using multivariable Cox regression analysis. Furthermore, we develop and validate a new postoperative scoring system for patients with spontaneous HCC rupture based on the these results.

Official Title
-----------------
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular Carcinoma: A Retrospective Study

Conditions
-----------------
Rupture, Spontaneous

Intervention / Treatment
-----------------
* Procedure: Liver resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Received partial hepatectomy; with Child A or B liver function. Exclusion Criteria: Without complete data；loss of follow-up; had reveived repeated transcatheter arterial chemoembolization before rupture; received non-radical resection.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Analysis before liver resection<br>Multivariate analysis of predictive factors associated with survival | Procedure: Liver resection<br>* Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.<br>|
| Different risk group<br>Low-risk group, moderate-risk group, high-risk group | Procedure: Liver resection<br>* Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.<br>|
| Model comparison<br>Comparison of models in predicting survival | Procedure: Liver resection<br>* Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival after partial hepatectomy | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival | Recurrence-free survival after partial hepatectomy | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
surgery, scoring system, hepatocellular carcinoma, homogeneity and discriminatory ability, survival
Effectiveness of Triclosan Coated Sutures in Preventing Leg Wound Infection After Coronary Artery Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess whether triclosan-coated sutures reduces wound infections compared to regular non-coated sutures, after saphenous vein harvesting in CABG patients.

Official Title
-----------------
Effectiveness of Triclosan Coated VICRYL\MONOCRYL Sutures in Preventing Leg Wound Infection Compared to POLYSORB\ BIOSYN Sutures in Patients After Coronary Bypass Surgery- a Randomized Controlled Trial

Conditions
-----------------
Complication of Coronary Artery Bypass Graft, Surgical Wound Infection

Intervention / Treatment
-----------------
* Drug: Triclosan
* Other: Conventional non-coated surgical sutures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older with written informed consent Male and female subjects Subjects scheduled for an elective and urgent CABG surgery that includes saphenous vein harvesting. Exclusion Criteria: Known allergy or intolerance to triclosan Different surgical prophylactic antibiotic regimen than common in the department. Continuous preoperative and predicted postoperative antibiotic treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Conventional sutures<br> | Other: Conventional non-coated surgical sutures<br>* Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure<br>|
| Experimental: Antiseptic sutures<br> | Drug: Triclosan<br>* Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| leg wound infection | Proportion of subjects with leg wound infection in research versus control group within 45 days of surgery according to CDC SSI criteria | Up to 45 days postsurgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibiotics administration | Amount of administered antibiotic for leg wound infection after surgery | Up to 45 days postsurgery | 
| Hospital Length of stay |  | Average of 7 days postsurgery | 
| Incidence of hospital re-admission due to leg wound infection |  | Within 45 days postsurgery |
Clinico-demographic Features of Patients With Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
The Global Burden of Disease Study 2010 found that acne vulgaris is the eight most common skin disease, with an estimated global prevalence (for all ages) of 9.38%.(1) Furthermore . Acne is a chronic inflammatory process that presents with two types of lesions clinically; non-inflammatory (closed and open) and inflammatory lesions (papules ,pustules ,nodules and post inflammatory pigmentary changes).

Official Title
-----------------
Clinico-demographic Features of Patients With Acne Vulgaris

Conditions
-----------------
Acne Vulgaris

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients of both sexes with clinical evident acne vulgaris any age Exclusion Criteria: no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 5 Days
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acne vulgaris patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index | (weight (kg)/height(m)2) | one year | 
| severity of acne vulgaris | Global acne grading system (GAGS): The GAGS is an acne grading system developed by Doshi et al . (13) In this grading system, lesions of acne vulgaris are divided into six sites: the forehead, right cheek, left cheek, nose, chin, and chest back.Each site has one factor score: the chin and nose are graded by one factor, the forehead and each cheek are graded by two factors and the chest and back are graded by three factors. Lesions are scored as follows: one point for a comedone, two points for a papule, three points for a pustule, and four points for a nodule. The lesion score of each site is calculated by the factor score, and the final score for that site is obtained. The total score varies between 1 and 44 and is evaluated as follows: mild falls between 1 and 18, moderate falls between 19 and 30, severe falls between 31 and 38, and very severe is over 39. | One year |
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.

Official Title
-----------------
Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

Conditions
-----------------
Anal Cancer

Intervention / Treatment
-----------------
* Radiation: Chemo-radiotherapy with IMRT technique
* Drug: Capecitabine
* Drug: Mitomycin C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CT/MRI diagnosed stage cT1-4N0-3; Histologically confirmed anal squamous carcinoma; KPS >= 70 Adequate organ function; No previous radiotherapy or chemotherapy; No surgery. Exclusion Criteria: Previous malignant cancer history; Allegic to 5-fu or MMC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chemo-radiotherapy with IMRT technique<br>Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy | Radiation: Chemo-radiotherapy with IMRT technique<br>* IMRT radiation technique; 50.4-54Gy/25F<br>Drug: Capecitabine<br>* Capecitabine 825mg/m2 PO BID<br>Drug: Mitomycin C<br>* Mitomycin C 10mg/m2 D1,29 iv<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate | To evaluate response rate of IMRT with chemotherapy | 8 weeks after IMRT | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | To assess the adverse events of IMRT with chemotherapy | from start of IMRT to 8 weeks after IMRT | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Radiotherapy, Anal cancer, IMRT
Motivational Enhancement for Spanish Speaking Individuals - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare a three-session Spanish version of Motivational Enhancement Therapy (MET) to standard treatment to see how well MET engages and retains Spanish-speaking clients in outpatient substance abuse treatment.

Official Title
-----------------
Motivational Enhancement for Spanish Speaking Individuals

Conditions
-----------------
Substance-Related Disorders

Intervention / Treatment
-----------------
* Behavioral: Behavior Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects included unless medical/psychiatrically unstable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Behavior Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment retention, drug and alcohol abstinence |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
behavioral intervention
A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop

Study Overview
=================
Brief Summary
-----------------
The efficacy, safety and acceptability of an investigational lubricant eye drop in subjects with dry eye will be evaluated in comparison with currently-available lubricant eye drops.

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: Carboxymethylcellulose sodium and Glycerin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild, Moderate, or Severe Dry Eye Symptoms and current eye drop use; Reduced tear stability or tear production Exclusion Criteria: NONE

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Carboxymethylcellulose sodium and Glycerin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dry Eye Symptoms |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular surface damage, tear stability, tear production |  |  |
Clinical Comparative Study to Validate Performance of SafeSed Prototype Monitoring Endoscopy Under Sedation

Study Overview
=================
Brief Summary
-----------------
SafeSed prototype monitors respiratory parameters by tracking chest movements with optical and accelerometer markers. The respiratory parameters are compared to respiratory parameters measured by a spirometer and a capnograph.

Detailed Description
-----------------
Patients performing endoscopy procedures under sedation at the gastro clinic will be monitored by SafeSed in addition to being monitored by capnography, used by an anaesthetist. All patients will be monitored using the same two techniques (SafeSed and Capnography). No clinical decisions will be made based upon the data generated by the SafeSed system. The data from all sources will be compared (post factum) to validate SafeSed performance. The data collected on the SafeSed prototype will not be used for treatment of the patient. The comparative analysis will be free vto be used by the sponsor.

Official Title
-----------------
SafeSed Validation Study, Comparing Performance to Capnography, as a Monitoring Technology of Respiratory Parameters

Conditions
-----------------
Apnea

Intervention / Treatment
-----------------
* Device: SafeSed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: class 1-3 per American Society Anesthesiologists Physical Status Classification Subject signed Informed Concent Form Exclusion Criteria: Pregnancy Unresolved pulmonary infection requiring active treatment Chronic pulmonary disease Any othe medical condition, that treating physician determines participating in the study is unadvisable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: SafeSed|Monitor respiratory parameters|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparative data of monitoring respiratory by 2 technologies | Validation of SafeSed performance by comparing to capnography. The respiratory rate (RR) and end tidal carbon dioxide (ETCO2) levels will be collected into a personal computer, and stored with a continuous time-stamp. RR, tidal volume (TD) and minute ventilatio (MV) calculations using the SafeSed markers chest movements will be stored at the same PC using the same time-stamp. Comparison will show correlation between deterioration events of respiratory parameters. This comparison will be the outcome of off-line analysis. | 4 months |
Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.

Study Overview
=================
Brief Summary
-----------------
Toric intraocular lens (IOL) is now widely used for the cataract surgery with preoperative corneal astigmatism. Symptomatic epiretinal membrane (ERM) is often treated with 25-gauge transconjunctival sutureless vitrectomy, resulting in good visual recovery. So far, however, limited information is available on the the stability of axis rotation, astigmatism correction, and improvement in uncorrected distance visual acuity, using astigmatism-correcting IOL in a 25-gauge transconjunctival sutureless vitrectomy combined with cataract surgery. In the current study, eyes with a preoperative corneal cylinder of more than 0.75 diopter had a triple procedure for idiopathic ERM using a toric IOL. Outcome measures will be the amount of IOL axis rotation, uncorrected visual acuity, corrected distance visual acuity, and corneal and refractive astigmatism up to 6 months postoperatively. We are expecting to show that postoperative IOL axis stability is similar to that reported for cataract surgery alone in vitrectomy (triple procedure) for idiopathic ERM with a toric IOL.

Official Title
-----------------
Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.

Conditions
-----------------
Corneal Astigmatism, Cataract, Epiretinal Membrane

Intervention / Treatment
-----------------
* Device: Vitrectomy with cataract surgery and toric IOL
* Device: Vitrectomy with cataract surgery and common IOL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preoperative corneal cylinder of more than 0.75 diopter Symptomatic idiopathic epiretinal membrane Symptomatic cataract Exclusion Criteria: Severe media opacity other cataract Eyes with other retinal disease, such as diabetic retinopathy, retinal vein occlusion, rhegmatogenous retinal detachment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cataract with ERM and astigmatism<br>Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter. | Device: Vitrectomy with cataract surgery and toric IOL<br> <br> Device: Vitrectomy with cataract surgery and common IOL<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The degree of IOL axis rotation from the end of surgery |  | Six months after the inplantation |
The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours. It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol

Official Title
-----------------
The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: escitalopram and tramadol
* Drug: placebo
* Drug: placebo and tramadol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Age: 18 - 45 years CYP2D6 phenotyped as extensive metabolizer CYP2C19 phenotyped as extensive metabolizer Exclusion Criteria: Alcohol or drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Escitalopram - tramadol | Drug: escitalopram and tramadol<br>* 10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9<br>* Other names: Ultram;|
| Experimental: B<br>Placebo - tramadol | Drug: placebo and tramadol<br>* 9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9<br>* Other names: Ultram;|
| Experimental: C<br>placebo - placebo | Drug: placebo<br>* placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC of (+)-M1 metabolite of tramadol |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dynamic pupillometry |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy subjects
Insulin Dependent Gestational Diabetes Mellitus: Randomized Trial of Induction of Labour at 38 and 40 Weeks of Gestation

Study Overview
=================
Brief Summary
-----------------
To evaluate the impact of induction of labour at 38 weeks with the induction of labour at 40 weeks in women with insulin dependent gestational diabetes mellitus on maternal and fetal outcome.

Conditions
-----------------
Gestational Diabetes Mellitus

Intervention / Treatment
-----------------
* Procedure: induction of labour


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women with insulin dependent gestational diabetes mellitus Exclusion Criteria: chronic inflammatory disease, autoimmune disease, pre-existing diabetes mellitus, previous cesarean section, multiple pregnancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: induction of labour|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |